Enovis Corporation (NYSE:ENOV) Holdings Raised by Tributary Capital Management LLC

Tributary Capital Management LLC raised its stake in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 8.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 611,525 shares of the company's stock after buying an additional 45,436 shares during the quarter. Enovis comprises approximately 2.0% of Tributary Capital Management LLC's holdings, making the stock its 9th largest position. Tributary Capital Management LLC owned about 1.07% of Enovis worth $23,366,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in shares of Enovis by 4.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,737 shares of the company's stock valued at $471,000 after acquiring an additional 458 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of Enovis during the 4th quarter valued at approximately $275,000. Swiss National Bank boosted its position in shares of Enovis by 2.5% during the 4th quarter. Swiss National Bank now owns 109,800 shares of the company's stock valued at $4,818,000 after acquiring an additional 2,700 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in shares of Enovis during the 4th quarter valued at approximately $402,000. Finally, Natixis Advisors LLC boosted its position in shares of Enovis by 52.8% during the 4th quarter. Natixis Advisors LLC now owns 19,381 shares of the company's stock valued at $850,000 after acquiring an additional 6,701 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Trading Down 14.8%

ENOV stock traded down $4.57 during midday trading on Friday, reaching $26.29. The company's stock had a trading volume of 3,974,842 shares, compared to its average volume of 930,257. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -1.88 and a beta of 1.70. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.32 and a current ratio of 2.55. Enovis Corporation has a 1 year low of $26.29 and a 1 year high of $49.83. The stock has a fifty day simple moving average of $32.75 and a two-hundred day simple moving average of $37.32.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The firm had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business's revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 earnings per share. On average, equities research analysts predict that Enovis Corporation will post 2.79 EPS for the current year.

Analysts Set New Price Targets

ENOV has been the subject of a number of research reports. Evercore ISI lowered their target price on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Canaccord Genuity Group lowered their target price on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. JMP Securities lowered their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Needham & Company LLC lowered their price target on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.60.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.